Sorrentino Expands Role to Support Goal of Bringing Innovative Technologies to Market
SALT LAKE CITY , Oct. 30, 2018 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of
data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments,
announces that John E. Sorrentino has been named Chairman of the Board in addition to his role as Chair of the Predictive
Scientific Advisory Board. Sorrentino has more than 35 years of senior management experience in the life sciences industry and
serves as Vice President and Chief Operating Officer of Pfizer Vaccine Research and Development. He replaced Merle Ferguson, who
will continue as a Director of the Company.
Sorrentino brings vast experience in R&D, commercialization and clinical laboratory management and has served in leadership
positions in public and private companies. Prior to joining Wyeth/Pfizer 15 years ago, he held executive positions in several
organizations that provided neonatal screening and related clinical services. Sorrentino is a noted expert in the healthcare
industry, having presented to state legislatures, the U.S. Congress and professional societies on a variety of healthcare and
policy issues.
“We are pleased to have John expand his involvement at our Company’s most senior level, as we introduce our first endometriosis
risk test, ARTguide™,” said Bradley C. Robinson, CEO of Predictive Technology Group. “John's experience, commitment and passion to
delivering improved, more comprehensive healthcare to patients will be of tremendous assistance in ensuring Predictive delivers on
our mission of preventing or eliminating disease for generations to come. We thank Merle for serving as Chairman and are delighted
he will continue to serve as a Board member.”
“We could not have found a more qualified and committed individual to serve as Chairman and lead the company’s corporate
governance,” said Ferguson. “As a longtime friend, I have seen first-hand John’s commitment to improving healthcare. I look forward
to his guidance as Predictive advances cutting-edge technologies to commercialization and we seek to list our securities on a
national exchange.”
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and
companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, Predictive Diagnostics and Predictive
Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue
products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that
assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively.
Additional information is available at Predtechgroup.com; Predrx.com and Predictivebiotech.com.
Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially
forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and
demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new
product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional
intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may
identify from time to time in the future.
Contact:
Investors
LHA Investor Relations
Jody Cain jcain@lhai.com
Kevin Mc Cabe kmccabe@lhai.com
310-691-7100
